245 related articles for article (PubMed ID: 23756600)
1. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.
Braak H; Zetterberg H; Del Tredici K; Blennow K
Acta Neuropathol; 2013 Nov; 126(5):631-41. PubMed ID: 23756600
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
Bloom GS
JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease. The density of amygdalar neuritic plaques is associated with the severity of neurofibrillary pathology and the degree of beta-amyloid protein deposition in the cerebral cortex.
Yilmazer-Hanke DM
Acta Anat (Basel); 1998; 162(1):46-55. PubMed ID: 9789108
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data.
Briani C; Ruggero S; Naccarato M; Cagnin A; Ricchieri GL; Pasqui L; Pizzolato G; Battistin L
J Neural Transm (Vienna); 2002 Mar; 109(3):393-8. PubMed ID: 11956959
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
7. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.
Musiek ES; Holtzman DM
Curr Opin Neurol; 2012 Dec; 25(6):715-20. PubMed ID: 23041958
[TBL] [Abstract][Full Text] [Related]
8. Neurofibrillary Tangles of Aβx-40 in Alzheimer's Disease Brains.
Lacosta AM; Insua D; Badi H; Pesini P; Sarasa M
J Alzheimers Dis; 2017; 58(3):661-667. PubMed ID: 28453491
[TBL] [Abstract][Full Text] [Related]
9. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
[TBL] [Abstract][Full Text] [Related]
10. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease.
Guo H; Albrecht S; Bourdeau M; Petzke T; Bergeron C; LeBlanc AC
Am J Pathol; 2004 Aug; 165(2):523-31. PubMed ID: 15277226
[TBL] [Abstract][Full Text] [Related]
11. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
Anthony IC; Norrby KE; Dingwall T; Carnie FW; Millar T; Arango JC; Robertson R; Bell JE
Brain; 2010 Dec; 133(Pt 12):3685-98. PubMed ID: 21126996
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls.
Han SH; Hulette C; Saunders AM; Einstein G; Pericak-Vance M; Strittmatter WJ; Roses AD; Schmechel DE
Exp Neurol; 1994 Jul; 128(1):13-26. PubMed ID: 8070517
[TBL] [Abstract][Full Text] [Related]
13. Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation.
Yilmazer-Hanke DM; Hanke J
Dement Geriatr Cogn Disord; 1999; 10(2):70-6. PubMed ID: 10026378
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-beta, tau, and dementia.
Takashima A
J Alzheimers Dis; 2009; 17(4):729-36. PubMed ID: 19542626
[TBL] [Abstract][Full Text] [Related]
15. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
16. [Alzheimer's disease: lesions and their progression].
Duyckaerts C; Colle MA; Delatour B; Hauw JJ
Rev Neurol (Paris); 1999; 155 Suppl 4():S17-27. PubMed ID: 10637934
[TBL] [Abstract][Full Text] [Related]
17. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Tau Aggregation in the Presence of Amyloid β.
Bennett RE; DeVos SL; Dujardin S; Corjuc B; Gor R; Gonzalez J; Roe AD; Frosch MP; Pitstick R; Carlson GA; Hyman BT
Am J Pathol; 2017 Jul; 187(7):1601-1612. PubMed ID: 28500862
[TBL] [Abstract][Full Text] [Related]
19. Where, when, and in what form does sporadic Alzheimer's disease begin?
Braak H; Del Tredici K
Curr Opin Neurol; 2012 Dec; 25(6):708-14. PubMed ID: 23160422
[TBL] [Abstract][Full Text] [Related]
20. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.
Siemers E; DeMattos RB; May PC; Dean RA
Biomark Med; 2010 Feb; 4(1):81-9. PubMed ID: 20387304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
